NCT06977542View on ClinicalTrials.gov

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2032

Conditions
TNBC, Triple Negative Breast Cancer
Interventions
DRUG

Ivonescimab

"a PD-1/ VEGF Bispecific Antibody, 20mg/kg, every 2 weeks;~Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide"

All Listed Sponsors
lead

Fudan University

OTHER